entertainment -WSS

entertainment

author：explore 2025-08-23 08:54:47 - browse：82824

a stethoscope and money – hospitals and health insurance coverage from STAT — Bright Health is officially leaving the health insurance market. The company has agreed to sell its Medicare Advantage plans to Molina Healthcare. Adobe

Bright Health Group has agreed to sell its Medicare Advantage plans to its publicly traded peer Molina Healthcare.

Regulators must approve the deal. But the pending sale of its Medicare Advantage business means the financially distressed Bright has exited the health insurance market that the company was founded on. It will solely operate roughly 70 physician clinics located in California, Texas, and Florida.

Molina agreed to pay $600 million for Bright’s 125,000 California Medicare Advantage enrollees, which equates to about $4,800 for each person. The federal government paid insurance companies almost $12,000, on average, for each MA enrollee in 2022. Molina said in a news release that Bright’s current book of business generates $1.8 billion of revenue, or more than $14,000 for each member.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Poor hospice wound care hurts patients and families

WSS

30 years of 'Listening to Prozac'

Childhood cancer progress stalls for Black, Hispanic kids: Report

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

PBM reforms clear House panel

Ransomware attacks on hospitals: Study outlines patient impact

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

focus

entertainment

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

U.K. considers world's first use of meningitis vaccine to address gonorrhea

How to save PrEP access — and even expand it

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Hollywood unions extend contract negotiations for actors

Morphosys mixed study results for blood cancer drug

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

focus

J&J to emphasize cancer drugs, stop much of its vaccine research

Gain of function research would be limited under House proposal

Childhood cancer progress stalls for Black, Hispanic kids: Report

Hospitals look to new technology to keep health care workers safe

Anthos stroke drug appears safer than common blood thinner

Fetal surgery at risk from Dobbs and new abortion restrictions

focus

entertainment

focus

entertainment